Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer;Estudo de aderência a capecitabina em pacientes com câncer colorretal e câncer de mama metastático

Arquivos de Gastroenterologia

Volumn 51, Issue 3, 2014, Pages 186-191

  de Figueiredo Junior, Adiel Goes ^a   Forones, Nora Manoukian ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast neoplasms; Colorectal neoplasms; Medication adherence; Questionnaires; Therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CLINICAL ARTICLE; COGNITION; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSPNEA; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; INSOMNIA; LOSS OF APPETITE; MALE; MEDICATION COMPLIANCE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; COHORT ANALYSIS; COLONIC NEOPLASMS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; QUESTIONNAIRE; RECTAL NEOPLASMS; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COHORT STUDIES; COLONIC NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECTAL NEOPLASMS;

EID: 84925224614     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032014000300004     Document Type: Article

References (32)

1. Aisner, J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am Journal Health-SysT Pharm. 2007,64:S4-7.
2. Anderson KR, Chambers CR, Lam N, Yau PS, Cusano F, Savoie ML, Sheikh N. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract. 2014 Feb 6. [Epub ahead of print]
3. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilization, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;CD000336. Review.
4. Bhattacharya D, Easthall C, Willoughby KA, Small M, Watson S. Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract. 2012;18:333-42.
5. Bourmaud A, Pacaut C, Melis A, Tinquaut F, Magné N, Merrouche Y, Chauvin F. Is oral chemotherapy prescription safe for patients? A cross-sectional survey. Ann Oncol. 2014;25:500-4.
6. Cantrell CR, Eaddy MT, Shah MB, Regan TS, Sokol MC. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44:300-3.
7. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7.
8. Cutsem EV, Findlay M, Osterwalder B. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1337-45.
9. Franceschini J, Jardim JR, Fernandes ALG, Jamnik S, Santoro IL. Reprodutibilidade da versão em português do Brasil do European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire em conjunto com seu módulo específico para câncer de pulmão. J Bras Pneumol. 2010;36:595-602
10. Fellowes D, Fallowfield LJ, Saunders CM, Houghton J. Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for 'welltolerated' treatments? Breast Can Res Treat. 2001;66:73-81.
11. Garcia RA. Cumplimiento terapêutico: qué conocemos de España. Aten Primaria. 2001;27:559-68.
12. Goodin S. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Health-Syst Pharm. 2007;64:S15-24.
13. Hoff PM, Cassid J, Schmoll HJ. The Evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. Oncologist. 2001;6:3-11.
14. Instituto Nacional de Câncer. Estimativas/2012. Brasil. Ministério da Saúde. Incidência de câncer no Brasil. 2012. Rio de Janeiro. [cited 2014 Feb 09]. Available from: http://www.inca.gov.br/estimativa
15. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167:540-50.
16. Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99:215-20.
17. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-5.
18. Mayer RJ. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol. 2007;20:25:4165-7.
19. Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360:2055-65.
20. O'Connor, PJ. Improving Medication Adherence: Challenges for Physicians, payers, and policy makers Arch Intern Med. 2006;166:17-25.
21. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-18.
22. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487- 97.
23. Partridge AH. Avom J, Wang PS, Winner EP. Adherence to therapy with oral antineoplastic agent. J Natl Cancer Inst. 2002;94:652-61.
24. Pullar T, Kumar S, Tindall H, Feely M. Time to stop counting the tablets? Clin Pharmacol Ther. 1989;46:163-8.
25. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther. 2004;42:409-22.
26. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009; 59:56-66.
27. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med.2003;348:2431-42.
28. Soran A, Nesbitt L, Mamounas EP, Lembersky B, Bryant J, Anderson S, Brown A, Passarello M. Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast and Bowel Project (NSABP) experience. Clin Trials. 2006;3:478-85.
29. Waterhouse DM, Calzone KA, Mele C, Brenner DE. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol. 1993;11:1189-97.
30. Walko CM, Lindley C. Capecitabine: a review. Clin Ther.2005;27:23-44.
31. World Health Organization. World Cancer Report, 2008. International Agency for Research on Cancer, Lyon. 2009. [cited 2014 Feb 16]. Available from: http:// www.iarc.fr/en/publications/pdfs-online/wcr/2008/wcr_2008.pdf
32. Wu, JY, Leung WY, Chang S, Lee B, Zee B, Tong PC, Chan JC. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ. 2006.333:522